The different VAF/cellularity cutoffs for tumor types could be related to differences in intratumoral heterogeneity of MGMT promoter methylation in IDH-mutant versus IDH-wildtype gliomas [51, 52]. This evidence concerns the gene IDH1 and central nervous system cancer.